Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer

International Journal of Cancer

Volumn 132, Issue 11, 2013, Pages 2714-2719

  Shahmoradgoli, Maria ^a   Riazalhosseini, Yasser ^a   Haag, Daniel ^a   Becker, Natalia ^a   Hovestadt, Volker ^a   Heck, Stefanie ^a   Sinn, Hans Peter ^b   Schneeweiss, Andreas ^c   Mannherz, Otto ^a   Sahin, Özgür ^a   Lichter, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

breast cancer; cell proliferation; drug resistance; estrogen receptor ; PPP1R15B; tamoxifen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN PHOSPHATASE 1 REGULATORY SUBUNIT 15B; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIZATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOSS; GENE OVEREXPRESSION; GENE SILENCING; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; PPP1R15B GENE; PRIORITY JOURNAL; RNA INTERFERENCE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; PROTEIN PHOSPHATASE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 84875600182     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27945     Document Type: Article

References (22)

1. Bertos NR, Park M,. Breast cancer-one term, many entities? J Clin Invest 2011; 121: 3789-96.
2. Huber KE, Carey LA, Wazer DE,. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol 2009; 19: 204-10.
3. Thuerigen O, Schneeweiss A, Toedt G, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24: 1839-45.
4. Wang DY, Done SJ, McCready DR, et al. A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis. Breast Cancer Res 2011; 13: R92.
5. Herr I, Debatin KM,. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98: 2603-14.
6. Igney FH, Krammer PH,. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-88.
7. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-7.
8. Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-9.
9. Sahin O, Frohlich H, Lobke C, et al. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol 2009; 3: 1.
10. de Souza Rocha Simonini P, Breiling A, Gupta N, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 2010; 70: 9175-84.
11. Esserman LJ, Berry DA, Cheang MC, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012; 132: 1049-62.
12. Lacroix M, Leclercq G,. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004; 83: 249-89.
13. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-27.
14. Kortlever RM, Higgins PJ, Bernards R,. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 8: 877-84.
15. Sicinski P, Donaher JL, Parker SB, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995; 82: 621-30.
16. Chanrion M, Negre V, Fontaine H, et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008; 14: 1744-52.
17. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607-16.
18. Altucci L, Addeo R, Cicatiello L, et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996; 12: 2315-24.
19. Cicatiello L, Addeo R, Sasso A, et al. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 2004; 24: 7260-74.
20. Mendes-Pereira AM, Sims D, Dexter T, et al. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA 2012; 109: 2730-5.
21. Ward A, Balwierz A, Zhang JD, et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2012.
22. Riggins RB, Schrecengost RS, Guerrero MS, et al. Pathways to tamoxifen resistance. Cancer Lett 2007; 256: 1-24.